▶ NAD+ · SUBTOPIC · DOSING LITERATURE

NAD+ Dosing Literature

For Laboratory Research Use Only. The content below describes dose ranges as reported in peer-reviewed publications. This page does not recommend any dose for human use. No clinical claim is made. Always consult the original source publication.

SCOPE OF THIS PAGE

This page documents the published-literature dose ranges that appear in trials and animal studies of NAD+. Every dose mention is bound to a citation (author, year, PMID where available). The PEPPUDEX wiki phrases these as descriptive observations of the research record, not as instructions to the reader.

ROUTES OF ADMINISTRATION IN PUBLISHED RESEARCH

The published research record for NAD+ reports the following route(s) of administration: Subcutaneous (research), Intravenous (research), Oral precursors (NR, NMN) widely used. Route selection in a study reflects pharmacokinetic considerations specific to that protocol and is not a recommendation for any human use of NAD+.

PHARMACOKINETIC HALF-LIFE

Published pharmacokinetic data report a half-life for NAD+ of approximately Short (minutes) in plasma; intracellular pools cycled continuously. Half-life is the kinetic parameter that frames the dosing rhythm chosen in trial design. It is a measurement, not a recommendation.

CITED DOSE RANGES IN THE LITERATURE

The peer-reviewed sources below report dose ranges, frequencies, and durations used in studies of NAD+. Refer to the original publication for full protocol detail.

Yoshino J, Baur JA, Imai S (2018) reports the NAD+ protocol used in NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR, published in Cell Metab. PMID 29249689. See the source for the protocol-level dose range, frequency, and duration. link
Imai S, Guarente L (2014) reports the NAD+ protocol used in NAD+ and sirtuins in aging and disease, published in Trends Cell Biol. PMID 24786309. See the source for the protocol-level dose range, frequency, and duration. link
Johnson S, Imai S (2018) reports the NAD+ protocol used in NAD+ biosynthesis, aging, and disease, published in F1000Res. PMID 29744033. See the source for the protocol-level dose range, frequency, and duration. link

DOSING Q+A FROM LITERATURE

The questions below summarise dosing-relevant entries from the literature record. Each answer is descriptive of published material and is not a recommendation.

▶ What is NAD+?

NAD+ is nicotinamide adenine dinucleotide in its oxidized form. It is an endogenous coenzyme found in every living cell, transferring electrons in glycolysis, the citric-acid cycle, and oxidative phosphorylation, and serving as obligate substrate of sirtuins, PARPs, and CD38.

▶ NAD+ vs NR vs NMN · which is best?

NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide) are NAD+ precursors that cross the plasma membrane more efficiently than full NAD+. Most clinical research uses precursors; direct NAD+ administration is debated. The precursors are most relevant for oral supplementation.

▶ What's the half-life of injected NAD+?

Short · on the order of minutes in plasma. Intracellular pools are cycled continuously through the salvage pathway. Most research interest is therefore in raising intracellular NAD+ via precursors that cross the plasma membrane.

▶ How is NAD+ stored?

Lyophilized NAD+ is stable at 2–8 °C protected from light for 12+ months. Reconstituted solution should be stored at 2–8 °C protected from light and aliquot-frozen for storage beyond 7 days. Avoid repeat freeze-thaw.

STORAGE OF THE REFERENCE COMPOUND

Lyophilized · 2–8 °C protected from light, 12+ months

Reconstituted · 2–8 °C protected from light, aliquot-freeze beyond 7 days

Storage conditions describe the stability of the research-grade reference material, not a dosing protocol.

RECONSTITUTION MATH (CALCULATOR)

The PEPPUDEX reconstitution calculator at /calculator returns volume-per-dose math given vial mg, BAC mL, and a target dose in mcg. The calculator performs arithmetic only. It does not recommend a dose. Any number entered by a researcher must come from their own protocol design or the cited literature.

REGULATORY CONTEXT

FDA · Not FDA-approved as a drug. NAD+ precursors NR and NMN have been subject to FDA enforcement actions in 2022–2024 regarding their classification as dietary supplements vs investigational drugs. Exogenous NAD+ salt remains a chemistry reagent under standard laboratory-use framing.

WADA · Not currently listed on the WADA Prohibited List (2026).

◀ NAD+ OVERVIEW MECHANISM ▶SAFETY PROFILE ▶

▶ LAST UPDATED · 2026-05-19